New Delhi: Four Covid-19 Vaccine Candidates are at various stages of human trials, while one, developed by the Genique Life Sciences, is in the pre-clinical stage of sophisticated, the Minister of Science and Technology Jitendra Singh said on Tuesday.
In a written response to questions at Rajya Sabha, Singh said the Cadila Healthcare Ltd.
DNA-based vaccine candidate was in three three clinical trials and had submitted temporary data to authorize emergency use.
Biological Vaccine Candidates E Ltd and Intrasal Bharat Biotech International Vaccine Candidates are in phase three clinical trials, while Gennova Biopharmaceuticals Ltd.
MRNA vaccine candidates are in phase one clinical trial, Singh said.
Gurgaon-based Genique Life Life Vaccine candidate is in the pra-clinical vaccine stage, he said.
At present, three vaccines – Serum Institute of India Covishield, Bharat Biotech’s Covaxin and Russian Vaccine Sputnik V – are being given in India.
Singh said the ‘Mission of Covid Surakha – The Mission of Development of Covid-19 India’s vaccine was announced as part of the third stimulus package’ Atmanirbhar Bharat 3.0 ‘to promote the research and development of the Indian Coronavirus vaccine.
“This mission supports the development of four vaccine candidates in the clinical stage of development and one vaccine candidate in advance pre-clinical stage of development.” Clinical Development of Vaccine Candidates is being carried out on the clinical trial site located PAN-India, “he added.
Responding to separate questions, Singh said India had taken a strong national and international research program to overcome Covid-19-related challenges, mainly focused on basic research, Diagnostics, therapeutic, and vaccine development in close collaboration with industry and beginner companies.
The necessary science and technology framework has been carried out to connect its scientific community with researchers from other countries such as Australia, Brazil, Denmark, Egypt, Israel, Japan, Portugal , Korean, Serbia, Singapore, Singapore, Singapore Slovenia, South Africa, England, USA and Vietnam to find a solution against Covid-19, he said.
Apart from bilateral cooperation, in he worked with Brazil, Russia, China and South Africa through BRICS program.
Joint calls launched include diagnostic areas, vaccines and t Erapeutik, re-granting drugs, artificial intelligence interventions, high performance computing for Covid-19 on various platforms ranging from supervision of diseases to diagnosis, he said.
Singh noted that India was one of the few countries in the world that had a promising pipe from vaccine candidates from various platforms in various stages of clinical development.
Under the partnership to start the Clinical Trade (PACT) initiative, the Biotechnology Department (DBT) partnered closely with the Ministry of External Affairs to strengthen the clinical trial capacity in neighboring countries.
Two series of training has been held with more than 2,400 participants in 20 sessions from 14 countries (Afghanistan, Bahrain, Bhutan, Gambia, Kenya, Maldives, Mauritius, Myanmar, Nepal, Oman, Somalia, Sri Lanka, Vietnam, and the United States).
As a global vaccine manufacturing hub, India has provided vaccines to other countries.
The current data from the external ministry indicates that to date, almost 19.86 million doses of covid-19 vaccines made in India have been distributed globally through Covax facilities, he added.
Singh said the intervention of yoga and meditation on student mental health, health workers and senior citizens during a pandemic-based rehabilitation program and yoga for covid-19 patients are some of India’s unique involvement compared to other countries in handling pandemics.
Pti pr aar aar 07202244 nnnn